Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.64 |
| ▸ | GSPT1 | P15170 | 4/20 | 0.64 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.64 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.51 |
| ▸ | IKZF2 | Q9UKS7 | 10/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62230 | 0.90 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL62227 | 0.86 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL60644 | 0.85 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL23240118 | 0.84 | CRBN (0.57) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL30313081 | 0.84 | CRBN (0.74) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL61307 | 0.83 | CRBN (0.72) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL68744 | 0.83 | CRBN (0.74) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL19752266 | 0.83 | CRBN (0.58) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL1413342 | 0.82 | CRBN (0.77) | CRBNGSPT1DDB1IKZF3CYP2C19 | |
| SCHEMBL61185 | 0.82 | CRBN (0.65) | CRBNGSPT1DDB1IKZF3CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358697-B1 | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER. | CELGENE CORP (US) | 2015-10-21 | — | — | EP | disclosed |